Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
Follow EDIT
Editas Medicine, Inc. (EDIT) Altman Z-score
Editas Medicine, Inc.'s Altman Z-score for fiscal 2025 is −13.39, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −13.39 | (6.09) |
| FY2024 | −7.30 | (6.63) |
| FY2023 | −0.67 | 0.60 |
| FY2022 | −1.28 | (8.11) |
| FY2021 | 6.84 | (5.45) |
| FY2020 | 12.28 | 10.11 |
| FY2019 | 2.17 | (0.08) |
| FY2018 | 2.25 | (1.03) |
| FY2017 | 3.28 | 1.66 |
| FY2016 | 1.62 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.63 | — | 0.76 | |
| Retained earnings / total assets | (8.73) | — | −12.22 | |
| EBIT / total assets | (0.86) | — | −2.83 | |
| Market value of equity / total liabilities | 1.14 | — | 0.69 | |
| Sales / total assets | 0.22 | — | 0.22 | |
| Altman Z-score | Distress zone | −13.39 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −29.91 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | 10.3× |
| DMAC DiaMedica Therapeutics, Inc. compare | 6.7× |
| ENTX Entera Bio Ltd. compare | 6.2× |
| SPRY ARS Pharmaceuticals, Inc. compare | 1.3× |
| PRTCY PureTech Health PLC Sponsored ADR compare | 0.8× |
| PRTA Prothena Corporation plc compare | −0.2× |
| EDIT Editas Medicine, Inc. | −13.4× |
| TECX Tectonic Therapeutic, Inc. compare | — |
| RZLT Rezolute, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets